Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Crit Rev Oncol Hematol. 2022 Sep;177:103771. doi: 10.1016/j.critrevonc.2022.103771. Epub 2022 Jul 26.
This study was undertaken to evaluate the prognostic significance of circulating tumour DNA (ctDNA) detection at different time periods in resectable non-small cell lung cancer (NSCLC). A comprehensive search strategy was conducted through the electronic platforms published up to June 2022. In total, 7 studies with 1138 patients were included. Patients with positive ctDNA have an increased risk of recurrence and mortality. The association between risk of recurrence and detectable ctDNA after surgery 3 days-2 weeks and 1-3 months was stronger than detected at 1 week before surgery. The predictive value of longitudinal detection ctDNA for recurrence and mortality was not stronger than at other time periods. In conclusion, ctDNA is a promising biomarker for predictive recurrence and survival in resectable NSCLC patients. The ctDNA detection after surgery 3 days-2 weeks with more reliably and feasible in identifying resectable NSCLC patients at high risk for recurrence.
本研究旨在评估在可切除的非小细胞肺癌（NSCLC）中不同时间点循环肿瘤 DNA（ctDNA）检测的预后意义。通过电子平台进行了全面的检索策略，检索时间截至 2022 年 6 月。共纳入 7 项研究，共 1138 例患者。ctDNA 阳性的患者复发和死亡风险增加。术后 3 天至 2 周和 1-3 个月检测到 ctDNA 与复发的相关性强于术前 1 周检测到的 ctDNA。纵向检测 ctDNA 对复发和死亡的预测价值并不强于其他时期。总之，ctDNA 是预测可切除 NSCLC 患者复发和生存的有前途的生物标志物。术后 3 天至 2 周检测 ctDNA 更可靠且可行，可识别出复发风险较高的可切除 NSCLC 患者。
